Literature DB >> 25010981

Theophylline therapy for Cheyne-Stokes respiration during sleep in a 41-year-old man with refractory arterial hypertension.

Jacek Wolf1, Ewa Świerblewska2, Hanna Jasiel-Wojculewicz2, Krzysztof Gockowski2, Bogdan Wyrzykowski2, Virend K Somers3, Krzysztof Narkiewicz4.   

Abstract

We report a case of a 41-year-old man who was noted to have position-dependent Cheyne-Stokes respiration with central sleep apnea (CSA) during sleep. The patient had multiple cardiovascular risk factors and target organ damages, including a history of two myocardial infarctions, transient ischemic attack, and chronic kidney disease. His hypertension was refractory to a number of antihypertensive medicines, however, a complete elimination of sleep-disordered breathing with oral theophylline treatment was paralleled by a significant BP fall with a subsequent need for reduction of antihypertensive drugs. Following these surprising observations we decided to withdraw theophylline from treatment (in-clinic). Theophylline discontinuation resulted in a gradual increase in BP and an urgent call for antihypertensive treatment modification. These observations suggest a potent hypotensive action of oral theophylline via Cheyne-Stokes respiration with CSA elimination. Our data suggest that CSA may be a mechanism that raises BP even during the daytime.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25010981      PMCID: PMC4077415          DOI: 10.1378/chest.13-2897

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  12 in total

1.  Population-based study of sleep-disordered breathing as a risk factor for hypertension.

Authors:  T Young; P Peppard; M Palta; K M Hla; L Finn; B Morgan; J Skatrud
Journal:  Arch Intern Med       Date:  1997 Aug 11-25

2.  Prospective study of the association between sleep-disordered breathing and hypertension.

Authors:  P E Peppard; T Young; M Palta; J Skatrud
Journal:  N Engl J Med       Date:  2000-05-11       Impact factor: 91.245

3.  Muscle sympathetic nerve activity during wakefulness in heart failure patients with and without sleep apnea.

Authors:  Jonas Spaak; Zoltan J Egri; Toshihiko Kubo; Eric Yu; Shin-Ichi Ando; Yasuyuki Kaneko; Kengo Usui; T Douglas Bradley; John S Floras
Journal:  Hypertension       Date:  2005-11-14       Impact factor: 10.190

4.  Prognostic value of nocturnal Cheyne-Stokes respiration in chronic heart failure.

Authors:  P A Lanfranchi; A Braghiroli; E Bosimini; G Mazzuero; R Colombo; C F Donner; P Giannuzzi
Journal:  Circulation       Date:  1999-03-23       Impact factor: 29.690

5.  Effect of theophylline on sleep-disordered breathing in heart failure.

Authors:  S Javaheri; T J Parker; L Wexler; J D Liming; P Lindower; G A Roselle
Journal:  N Engl J Med       Date:  1996-08-22       Impact factor: 91.245

6.  Involvement of cyclic nucleotides in renal artery smooth muscle relaxation.

Authors:  A J Karsten; H Derouet; M Ziegler; R E Eckert
Journal:  Urol Res       Date:  2002-10-01

7.  Theophylline therapy for near-fatal Cheyne-Stokes respiration. A case report.

Authors:  C A Pesek; R Cooley; K Narkiewicz; M Dyken; N L Weintraub; V K Somers
Journal:  Ann Intern Med       Date:  1999-03-02       Impact factor: 25.391

8.  Sleep apnoea in a hypertensive population.

Authors:  A Kales; E O Bixler; R J Cadieux; D W Schneck; L C Shaw; T W Locke; A Vela-Bueno; C R Soldatos
Journal:  Lancet       Date:  1984-11-03       Impact factor: 79.321

9.  Differential effects of theophylline on sympathetic excitation, hemodynamics, and breathing in congestive heart failure.

Authors:  Stefan Andreas; Hartwig Reiter; Lars Lüthje; André Delekat; Rolf W Grunewald; Gerd Hasenfuss; Virend K Somers
Journal:  Circulation       Date:  2004-10-04       Impact factor: 29.690

10.  Increased mortality associated with Cheyne-Stokes respiration in patients with congestive heart failure.

Authors:  P J Hanly; N S Zuberi-Khokhar
Journal:  Am J Respir Crit Care Med       Date:  1996-01       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.